Jewish World Review March 28, 2001 / 4 Nissan, 5761
James K. Glassman
Lots of really smart people believe that the most exciting technical advances in coming years will come from biotechnology. The mapping of the human genome has given all of us hope in the fight against deadly diseases, and the commercial possibilities seem almost as intriguing. The problem for investors is figuring out which companies are likely to deliver effective therapies and consistent earnings.
Many biotech companies lose money for years while they attempt to push a candidate drug all the way through the approval process at the Food and Drug Administration. Many never make it, and, in any case, itís extremely difficult to pick the winners in this high-stakes game of hit-or-miss. An alternative strategy is to invest in companies that provide products and services to biotech companies. If you donít want to guess whoís going to cure cancer, but you believe that a lot of money will continue to flow into the search, think about investing in the people who outfit the cure-hunters.
Itís a tried-and-true strategy of profiting from a gold rush Ė selling picks and shovels to the miners. As a matter of fact, Levi Strauss got rich selling its blue jeans to 19th Century fortune-seekers in California. More recently, companies like Cisco and Sun Microsystems made fortunes selling tools to people chasing the Internet dream. How do you make money on the Internet? Online merchants and publishers still arenít sure, but they bought a lot of Sun and Cisco gear trying to figure it out. In the last year, of course, these two stocks have been taken out and shot by investors as tech customers cut spending, but long-term holders have been rewarded handsomely.
Investing in suppliers to biotech firms isnít sexy Ė none of these companies will change the world. But they may be able to ride a wave of spending on medical research. Among the more established firms in this arena are Becton Dickinson (BDX), Beckman Coulter (BEC) and Apogent Technologies (AOT). They make thousands of products used in modern medical research, from robots that automate laboratories to special furnaces to the plastic ware and other equipment used to culture cells, as well as more high-tech products for analyzing human and animal tissue. Applied Biosystems (ABI) is a tracking stock for the part of Applera Corp. that makes gene-sequencing machines. In fact, ABIís machines were used to map the human genome.
All four of the stocks mentioned above trade at reasonable price/earnings ratios but may not have the upside potential of some smaller, younger companies. Still, the large firms represent a solid way to anticipate large spending on medical research. Among the more aggressive investments, Affymetrix (AFFX) and Molecular Devices (MDCC) are focused on more high-tech products to analyze cells.
One company I find particularly intriguing is Albany Molecular Research
(AMRI), which provides drug discovery and development services, chemistry
research and manufacturing for a growing number of biotech and
pharmaceutical companies. This may not sound like the cutting edge of
biotechnology, being the contractor for innovative companies, but AMRIís
customers obviously place a high value on its services. In calendar year
2000, Albany squeezed $24 million in earnings out of its $67 million in
revenues. Those numbers represent a 71 percent increase in earnings and a
200 percent increase in revenues for the year. Little wonder that AMRI
ranked No. 2 on Forbes magazineís most recent list of Americaís 200 best
small companies. And itís not hard to believe that the demand for medical
research services will continue to
03/22/01: The Joy of Debt: The last thing we should want is a U.S. Treasury flush with cash